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Background: The VP3 protein of goose parvovirus (GPV) or Muscovy duck parvovirus (MDPV), a major structural
protein, can induce neutralizing antibodies in geese and ducks, but monoclonal antibodies (MAbs) against VP3
protein has never been characterized.
Results: Three hybridoma cell lines secreting anti-GPV VP3 MAbs were obtained and designated 4A8, 4E2, and 2D5.
Immunoglobulin subclass tests differentiated them as IgG2b (4A8 and 4E2) and IgG2a (2D5). Dot blotting assays
showed that three MAbs reacted with His-VP3 protein in a conformation-independent manner. A competitive
binding assay indicated that the MAbs delineated two epitopes, A and B of VP3. Immunofluorescence assay
showed that MAbs 4A8, 4E2, and 2D5 could specifically bind to goose embryo fibroblast cells (GEF) or duck
fibroblast cells (DEF) infected with GPV and MDPV. Dot blotting also showed that the MAbs recognized both nature
GPV and MDPV antigen. Western blotting confirmed that the MAbs recognized VP3 proteins derived from purified
GPV and MDPV particles. The MAbs 4A8 and 2D5 had universal reactivity to heterologous GPV and MDPV tested in
an antigen-capture enzyme-linked immunosorbent assay.
Conclusions: Preparation and characterization of these the MAbs suggests that they may be useful for the
development of a MAb-capture ELISA for rapid detection of both GPV and MDPV. Virus isolation and PCR are
reliable for detecting GPV and MDPV infection, but these procedures are laborious, time-consuming, and requiring
instruments. These diagnosis problems highlight the ongoing demand for rapid, reproducible, and automatic
methods for the sensitive detection of both GPV and MDPV infection.
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Parvovirus infection is widespread in most goose farm-
ing countries of Europe and Asia and causes serious eco-
nomic loss [1,2]. Goose parvovirus (GPV) can cause
disease characterized by ascites, enteritis, myocarditis,
and hepatitis with high mortality and morbidity in geese
(Anser anser) and Muscovy ducks (Cairina moschata)
[3-5].
The genomes of GPV and Muscovy duck parvovirus
(MDPV) are 5106 nucleotides in length and contain two
open reading frames (ORF). The left ORF encodes the
regulatory proteins, whereas the right ORF encodes
three capsid proteins: VP1, VP2, and VP3. VP1, VP2,* Correspondence: liuming04@126.com; yunzhang03@yahoo.com
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reproduction in any medium, provided the orand VP3 are derived from the same gene by differential
splicing, and VP2 and VP3 are contained within the
carboxyl-terminal portion of VP1 [6-8]. The VP1 poly-
peptides of GPV and MDPV share 88% amino acid se-
quence identity [7-9], which allows cross-protection of
Muscovy ducks against MDPV infection by vaccination
with attenuated GPV [10]. The VP3 protein is the most
abundant of the three core proteins [11] and can induce
neutralizing antibodies in GPV- or MDPV-infected
waterfowls [12]. Recently, a new divergent MDPV (PSU-
3101) has been isolated, which showed 84.5% sequence
identity with other MDPV isolates and 84.6% identity
with GPV isolates [13].
Many methods have been developed for the diagnosis
of GPV or MDPV infections, including agar gel precipi-
tation, the virus neutralization test [14], Western blot-
ting assays [15], virus antigen-based enzyme-linked. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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based ELISA [17], a plaque neutralization assay [18], an
indirect fluorescent antibody test [19], polymerase chain
reaction (PCR) for the rapid detection of GPV DNA
[20], and quantitative analysis of waterfowl parvovirus
by real-time PCR [21]. However, these methods are gen-
erally time-consuming and labor-intensive, and require
sophisticated instruments. Here, we produced and char-
acterized three MAbs against bacterially expressed VP3
protein of GPV. Contrary to currently available PCR
tools, the MAbs could not discriminate between GPV
and MDPV infection; however, due to 4A8 and 2D5 uni-
versal reactivity to both GPV and MDPV, the MAbs are
ideal candidates for both GPV and MDPV clinical diag-
nosis in an antigen-capture ELISA.Results
Production and characterization of MAbs
Three weeks after cell fusion, the hybridoma cell lines
secreting anti-VP3 antibody were screened by means of
an ELISA. Three MAbs directed against VP3 were
selected and subcloned at least three times using the
limiting dilution method. Hybridomas were selected to
produce MAbs in mice and the ascitic fluids were used
for further characterization. The isotypes of the MAbs
were IgG2b (4A8 and 4E2) and IgG2a (2D5). Concentra-
tions of immunoglobulin ranged from 0.40 to 17.53 μg/ml.
Effect of denaturation of VP3 on MAb recognition
The expressed His-VP3 proteins were denatured by
boiling in SDS and 2-mercaptoethanol, and subjected
to Western blotting; three MAbs still recognized them








Figure 1 Reactivity of Ep22 VP3 MAbs to the E coli expressed
pET30-VP3 and pET30a vector. Lane 1, 4, and 7, protein molecular
marker; lane 2, 5, and 8 E. coli expressed pET30-VP3; lane 3, 6, and 9
E.coli expressed pET30a vector. MAb 4A8(A), MAb 4E2(B), and MAb
2D5(C).required for antibody binding, antigens containing His-
VP3 were examined by using a dot blotting assay. All
MAbs recognized the nature structure of His-VP3 in
TNE buffer (Figure 2), but did not react with the 6.7 His
proteins. Three major proteins (VP 1, VP 2 and VP 3)
were identified by SDS-PAGE in a purified Muscovy
duck (91, 78 and 58 kDa) and goose (85, 61 and 57 kDa)
parvovirus virions [22-24]. Western blotting analysis
showed that MAbs reacted with molecular weight of 90,
77, and 64 kDa of VP1, VP2, and VP3 from denatured
GPV EP22 (represented by Figure 3, lane 2) and MDPV
J3D6 (represented by Figure 3, lane 4) antigen, which
were similar to VP1, VP2, and VP3 of goose parvovirus
and Muscovy duck parvovirus. MAbs did not recognize
blank allantoic fluids (represented by Figure 3, lane 3).
This result suggested that the MAbs recognized VP3
proteins derived from purified GPV and MDPV
particles.Detection of native VP3 protein by immunofluorescence
assay
Immunofluorescence assay was performed on EP22 and
J3D6 infected GEF/DEF to assess whether the MAbs
recognize the native-form of VP3 protein of GPV and
DPV. Three MAbs strongly reacted with EP22 infected
GEF cells or J3D6 infected DEF (represented by
Figure 4A and B). All uninfected cells showed no reac-
tion to any MAbs (represented by Figure 4C). Immuno-
fluorescence assay also indicates that the MAbs bound
to the authentic viral VP3 protein, which located pre-
dominantly within the nuclei without affecting the nu-
cleoli and rarely within the cytoplasm of infected cells,
which is consistent with previous report [22,23]. In some
cells GPV/MDPV appeared as granules scattered
throughout the nucleus (indicated by red arrow), while
in other cells GPV/MDPV were distributed homoge-
neously in nuclei (indicated by purple arrow or in
Figure 4B).1 2 3
6.7 His protein
His-VP3 Protein
Figure 2 Dot blotting assay of MAbs to the His-VP3 and His
proteins. Lane 1, MAb 4A8; lane 2, MAb 2D5; lane 3, MAb 4E2.
1 2 3 4
Figure 3 Western blot analysis of purified GPV and MDPV to
MAbs. Lane 1: protein molecular weight marker; Lane 2: purified




4A8  2D5 4E2
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Figure 5 Dot blotting assay of MAbs to native GPV and MDPV
particles. Lane 1, MAb 4A8, lane 2, MAb 2D5; lane 3, MAb 4E2.
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Dot blotting assays showed that three MAbs recognized
both GPV and DPV native particles, while blank allan-
toic fluids were not detected by any MAbs (Figure 5).
Avidity of the MAbs to VP3
The amount of MAbs bound to the VP3 proteins can be
quantified within the linear range of absorbance. This
offers an estimation of the relative avidity of MAbs forA B
Figure 4 Detection of VP3 protein by indirect immunofluorescence as
B: MDPV infected MDF, C: Mock infected cells. No special fluorescence wastheir binding proteins. The binding degrees of the MAbs
to the His-VP3, using ELISA titration, indicated that the
three MAbs saturated fat dilutions ranging from 10-1 to
10-1.6. The three MAbs retained their binding capacity
after coupling to HRP, and the dilution range of satur-
ation was 101 to 102. No saturation was apparent with
the remaining HRP-MAbs (data not shown).
Epitopes mapping
The appropriate concentrations for the competitive
binding assay were determined by using the dose–re-
sponse curves plotted for the unconjugated and HRP-
conjugated MAbs (data not shown). Each of the three
MAbs was used both as a competitor and as an HRP-
conjugated probe. The percentage of competition was
100% in the presence of a saturating unlabeled homolo-
gous antibody. Two distinct epitopes on VP3 were found
and designated A and B (Table 1). MAb 4A8 recognized
epitope A, whereas 4E2 and 2D5 recognized epitope B.C
say on cells infected with EP22 and J3D6. A: GPV infected GEF,
found on normal cells (400 ×).




4A8 + + –– ––
Epitope B
4E2 –– + + + +
2D5 –– + + + +
Yin et al. Virology Journal 2012, 9:288 Page 4 of 7
http://www.virologyj.com/content/9/1/288Detection of VP3 antigens
MAbs 4A8 and 2D5, which recognized epitopes A and
B, respectively were selected to test their cross-reactivity
with other heterologous GPV strains (G3, GD, and HE)
or MDPV (J3D6 and KL) in the ELISA. The relative
binding to heterologous GPV or MDPV isolates was
expressed as a percentage of the absorbance obtained
with GPV EP22, which was set at 100. Binding was rated
as strong if it was more than 50%, significant if it was
25%–50%, and negative if it was less than 25%. The
results indicated that the VP3 in the cell extracts pre-
pared from CGBQ cells infected with heterologous GPV
strains or from MDEF cell infected with DPV was cap-
tured by the anti-VP3 antiserum. The binding rated for
GPV and MDPV were 100% and there were no appre-
ciable differences for GPV in the binding of the different
MAbs tested. As expected, negative results were obtained
with mock-infected CGBQ cells or DEF cells (< 25%).
MAbs 4A8 and 2D5 strongly recognized all tested GPV
and MDPV strains, suggesting that epitopes A and B are
commonly present on the VP3 of GPV and MDPV strains
and indicating that 4A8 and 2D5 are suitable for detect-
ing GPV and MDPV isolates.
Discussion
Here, we developed and characterized three MAbs
against goose parvovirus VP3 protein. Our results show
that antigen preparations containing the expressed His-
VP3 protein of GPV could induce the production of
MAbs. After screening and sub-cloning, three MAbs
against His-VP3 were isolated and characterized.
Western blotting and immunofluorescence assay indi-
cated that the MAbs bound to the authentic viral VP3
protein of GPV and MDPV and that this protein loca-
lized mainly in the nucleus of infected cells, which is
consistent with a previous report [22,23]. The MAbs
bound to the His-VP3 in its native conformation, and
when SDS and 2-mercaptoethanol were used to denature
the His-VP3 protein, this binding was retained, indicat-
ing that the epitopes were not affected by breaking of di-
sulfide bonds. This finding suggests that the MAbs
binding was conformation-independent. Competitive
binding assays were used to determine the epitopes
recognized by the MAbs based on the notion that aMAb binding to a specific site can block the attachment
of another MAb to the same site. Two epitopes, A and
B, almost completely inhibited the binding of HRP-
coupled MAbs recognizing the same epitope, but no
competition was obtained among MAbs recognizing epi-
tope A or B. Dot blotting analysis showed that the epi-
topes on the VP3 recognized by three MAbs were also
present on the native viral VP3 of GPV and DPV parti-
cles, which is consistent with immunofluorescence assay
analysis. By the immunofluorescence assay, it could also
identify the GPV/MGPV antigen with MAbs because of
its distinctive nuclear localization within infected cells,
which consistent with previous report [22]. A similar
finding was obtained when MAbs specificities were ana-
lyzed by Western blotting. Three major proteins (VP1,
VP2 and VP3) MW are in consistent with previously
reports of Muscovy duck (91, 78 and 58 kDa) and goose
(85, 61 and 57 kDa) parvovirus virions [22-24].
Whether epitope A or B is involved in any biological
function has not yet been determined; however, these
epitopes, are highly conserved among GPV and MDPV
strains, as the MAbs recognized both epitopes on all
field strains tested. It has been suggested that the epi-
topes recognized by B19 [25] are involved in heparan
sulfate binding. The region containing the epitope might
function as the primary receptor attachment site of B19,
yet it does not correspond to the globoside binding site
[26]. This reason for this discrepancy requires clarifica-
tion. Accordingly, to determine whether VP3 of GPV/
MDPV is involved in heparan sulfate binding, we are
currently preparing deletion mutant proteins of GPV/
MDPV VP3 to assess with the MAbs described here.
Three MAbs successfully detected the native-form of
the VP3 protein in infected cells, as well as in viral parti-
cles. Therefore, these MAbs may be useful in the devel-
opment of sensitive methods to detect GPV and MDPV,
such as immunoblot assays, immunofluorescence assays,
and antigen-capture ELISA. Antigen-capture ELISA
using antivirus antibodies is ideal for large screening,
quantitative analysis of viral antigens or virus titres be-
cause of its high sensitivity, reproducibility, and automa-
tion. In this study, we generated three positive clones
that secreted specific and highly reactive antibodies
against VP3 protein for use in diagnostic methods.
MAb-capture ELISA clearly differentiated between
GPV-/MDPV- and mock-infected samples, as demon-
strated by absorbance values, suggesting that non-specific
reactions could be markedly reduced in a MAb-capture
ELISA. Two of the MAbs (4A8 and 2D5) recognized
GPV and MDPV VP3 at different sites that were highly
conserved in all GPV and MDPV strains tested. Thus, a
MAb-capture ELISA using MAbs 4A8 and 2D5 would
appear to be an acceptable future screening method for
the detection of GPV and MDPV in infected birds.
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In summary, the results of this study provide important
information about MAbs against the GPV VP3 protein.
In particular, the MAbs could contribute to the develop-
ment of a MAb-capture ELISA for rapid detection of
GPV and MDPV. GPV and DPV antigen could be
detected with these MAbs in GPV infected cells in Im-
munofluorescence assay. Although virus isolation and
PCR are reliable methods to detect GPV and MDPV in-
fection, they are laborious, time-consuming, and requir-
ing specialized instruments. These diagnosis problems
highlight the need for alternative rapid, reproducible,
and automatic methods to detect GPV and MDPV.
Methods
Cells and viruses
Heterologous goose parvoviruses EP22, G3, GD, HE,
and Muscovy duck parvovirus (MDPV) J3D6 were used
in this study. The GPV Ep22, G3, GD, and HE strains
were isolated from the livers dead geese with hepatitis in
China in 2001, 1995, 1989, and 2007, respectively, as
described previously [27]. MDPV J3D6 and KL strains
were isolated from dead Muscovy ducks in 1999 and
2008. VP3 gene of EP22, G3, GD, and HE diverge 4.1 to
4.7% at amino acids level. VP3 of J3D6 and KL showed
85.9%-88.7% identities to those of GPV. GPV were pro-
pagated in goose CGBQ cells (AATC CCL-169) or goose
embryo fibroblast cells (GEF) or in the allantoic sacs
of 14-day-old embryonated goose eggs. MDPV J3D6
and KL was propagated in 13-day-old Muscovy duck
embryonated eggs.
Virus purification
The allantoic fluids containing EP22 and J3D6 were cen-
trifuged at 20 000 × g for 15 min. The supernatants were
layered onto 30% (w/w) sucrose solution and concen-
trated by ultracentrifugation (109 000 × g, 10 h, 4°C).
The pellets were suspended in PBS, clarified at 5000 × g
for 20 min and ultracentrifuged at 109 000 × g for 2.5 h.
The purified viruses were stored at −20°C until used.
Antigen preparation
The VP3 protein used for the production and
characterization of MAbs was synthesized in Escherichia
coli BL21 (DE3) as described previously [17]. The
expressed His-VP3 and 6.7-kDa His tag proteins were
purified by using a Ni-NTA kit (Qiagen, Valencia, CA).
The 6.7-kDa His tag protein was used as a negative con-
trol during screening for specific antibodies to VP3 in an
ELISA.
Monoclonal antibodies production
BALB/C mice (Harbin Veterinary Experimental Central)
were immunized intraperitoneally with 30 μg of antigencontaining the VP3 fusion protein in complete Freund’s
adjuvant and boosted twice with the same amount of
antigen in incomplete Freund’s adjuvant at 2-week inter-
vals. Six weeks after the initial immunization and 4 days
before the mice were sacrificed for the preparation of
hybridomas, a final boost was given via the same route
with 30 μg of the same antigen. MAbs were produced by
using techniques similar to those described previously
[28]. Briefly, spleens were removed from the immunized
mice, and their splenocytes were fused with NS1 mye-
loma cells. Hybridoma cell lines secreting antibodies
against the VP3 protein were screened and subcloned at
least three times by use of a limiting dilution method
and ascitic fluids were prepared with the cloned hybri-
domas in BALB/C mice. All mice were maintained in
the animal facility at Harbin Veterinary Research Insti-
tute under standard conditions prescribed by the Institu-
tional Guidelines. The study protocol was approved by
the Institutional Animal Care and Use Committee.
Serological screening
Hybridoma culture supernatants or mouse ascetic fluids
were screened for antibodies in an indirect ELISA as
described for the antibody binding assay. Antibodies that
bound to the VP3 protein but failed to bind the 6.7-kDa
protein were selected for sub-cloning.
Isotyping
Isotypes of the produced MAbs were determined by
using a Mouse Immunoglobulin isotyping kit (Zymed
Laboratories, Inc.) according to the manufacturer’s
instructions.
Western blotting and dot blotting assays
The samples of expressed His-VP3/His proteins and
purified GPV EP22 and MDPV J3D6 were denatured by
boiling in SDS and 2-mercaptoethanol. The boiled sam-
ples were subjected to 10% SDS-PAGE and transferred
to nitrocellulose membranes for Western blotting ana-
lysis. The membranes were probed with different MAbs
followed by a secondary HRP-conjugated goat anti-
mouse antibody (KPL, MD, USA). The purified GPV and
MDPV antigen or blank allantoic fluids (as a negative
control) were used for Western blotting assays. The na-
tive antigens containing His-VP3 and the 6.7 His protein
(as a negative control) were used for dot blotting assays.
The membranes were then probed with the same MAbs
as for Western blotting assays.
Detection of native VP3 protein by immunofluorescence
assay
GEF and DEF infected with Ep22 and J3D6 strain (at
10 M.O.I. TCID50/cell), respectively, incubated at 37°C
for 48 h. The cells were fixed with cold methanol for
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and negative normal mouse serum for 1 h at 37°C.
Bound antibodies were visualized using fluorescent con-
jugated antibodies against mouse IgG (1:500 dilutions)
under a fluorescence microscope.
Effect of native structure of VP3 on MAbs recognition
To determine if a native GPV or MDPV particles could
be recognized by three MAbs, the purified GPV EP22
and MDPV J3D6 particles (about 1 μg) and blank allan-
toic fluids as negative control were spotted onto nitro-
cellulose membranes for dot blotting assays.
Coupling of horseradish peroxidase to MAbs
Immunoglobulin fractions were isolated from ascetic
fluids by precipitation at 4°C with an equal volume
of saturated ammonium sulfate (pH 7.0), and then puri-
fied by using an affinity column of protein G-agarose
(Boehringer Mannheim). Antibodies were coupled to
HRP by means of the periodate method [29] and stored
at -20°C.
Determination of MAbs titres
The titers of the MAbs were determined by using
an ELISA. The purified His-VP3 protein (0.1 μg) was
coated onto plate wells at 37°C for 2 h. The plates (Nunc
MaxiSorpW flat-bottom 96 well plate) were then washed
three times with washing buffer (0.01 M phosphate-
buffered saline, pH 7.2, 0.05% Tween 20) and blocked
with 100 μl of TNE buffer containing 2.5% bovine serum
albumin. After washing, two-fold serial dilutions of 1 μg/ml
uncoupled or HRP-coupled MAbs were added and incu-
bated for 1 h. For uncoupled MAbs, an additional 50 μl of
HRP-coupled goat anti-mouse antibodies (KPL, MD, USA)
was added. Absorbance was read at 405 nm with a Micro-
plate Reader (BIO-RAD). The level of binding for the rela-
tive activity assessment was measured from the resulting
dose–response curve.
Antibody binding assay
For the competitive binding assay, the amount of MAb
binding in the ELISA was determined for MAbs
uncoupled or coupled with HRP [30]. Briefly, for HRP-
unconjugated MAb determination, ELISA plates were
coated with 0.1 μg of purified VP3 per well at 37°C for
2 h. After washing, 100 μl of TNE buffer containing
2.5% bovine serum albumin was added to each well to
saturate all unbound sites. After washing, 100 μl of puri-
fied MAb serially diluted with TNE buffer containing 1%
bovine serum albumin was added and incubated for 2 h
at 30°C. After washing, 50 μl of a 1:500 dilution of HRP-
conjugated goat anti-mouse IgG serum was added and
incubated for another 1 h. The enzymatic activity was
determined after 20 min of incubation by the addition of30 ml of 1% sodium azide. Absorbance was measured at
405 nm. For HRP-conjugated MAb determination, the
same procedures were carried out except that HRP-
conjugated MAbs were directly added to the antigen-
coated plates without using the HRP-conjugated goat
anti-mouse antiserum. The level of maximum binding
for the relative activity assessment and the MAb concen-
tration at which 50% binding occurred were obtained
from the resulting dose–response curve.Competitive binding assay
The competitive binding assay was performed similarly
to the procedures described above, except that a mixture
of the HRP-conjugated MAbs was used at twice the con-
centration, giving half-maximal binding. Unconjugated,
competing antibodies at different concentrations were
also added simultaneously. The competition between
two MAbs for the same site was correlated to their rela-
tive avidities and concentrations. A spectrum of dose-
related interference was tested. Non-specific binding
without antigens was used to represent the background.
The degree of competitive binding was measured from
the absorbance at 405 nm in the presence or absence of
unconjugated competing antibodies. Competition was
rated as strong (++) if it was more than 60%, significant
(+) if it was more than 30%, and negative (–) if it was
less than 30%.Cross-reactivity of MAbs to heterologous GPV strains
To study the cross-reactivity of the MAbs for various
GPV and MDPV strains in an antigen-captured ELISA,
we tested three GPV (G3, GD, and HE) and MDPV
(J3D6 and KL) field isolates. MAbs (4A8 and 2D5) were
used to prepare an antigen-capture ELISA and compared
with a polyclonal antibody against GPV EP22. Briefly,
100 μl of mouse anti-VP3 polyclonal antibodies (1:200)
was coated onto ELISA plates. After washing and block-
ing, 100 μl of cell extracts of GEF or DEF infected with
GPV or MDPV isolates or from mock-infected cells was
added and incubated for 1 h at 37°C. For the MAb reac-
tions, 50 μl of HRP-conjugated MAbs (1:1000) was
added as the primary antibody. To determine whether
the VP3 present in each cell extract from cells infected
with each GPV and MDPV isolate was captured by the
anti-VP3 antiserum, goose antiserum against GPV EP22
and HRP-coupled goat anti-goose antiserum were used
as a primary and secondary antibodies, respectively. Ab-
sorbance was measured at 405 nm. Binding to the heter-
ologous virus was expressed as a percentage of the
absorbance obtained with GPV EP22, which was set at
100. Binding was rated as strong if it was more than
50%, significant if it was 25%–50%, and negative if it was
less than 25%.
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